Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

S Ehmsen; L H Jakobsen; M E Lendorf; R L Eefsen; L Bentsen; A S Knoop; N Aggerholm-Pedersen; H Skuladottir; J Herrstedt; L H Jensen; C Rotbøl; M B Damm; K Wedervang; A Glenthøj; J Ryg; H Frederiksen; A R Kodahl

doi:10.1080/0284186X.2021.1889659

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

S Ehmsen, L H Jakobsen, M E Lendorf, R L Eefsen, L Bentsen, A S Knoop, N Aggerholm-Pedersen, H Skuladottir, J Herrstedt, L H Jensen, C Rotbøl, M B Damm, K Wedervang, A Glenthøj, J Ryg, H Frederiksen, A R Kodahl

Research output: Contribution to journal › Journal article › Research › peer-review

34 Downloads (Pure)

Abstract

BACKGROUND: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis.

METHODS: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study's primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen.

RESULTS: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39).

CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.

Original language	English
Journal	Acta Oncologica
Volume	60
Issue number	7
Pages (from-to)	859-865
Number of pages	7
ISSN	0284-186X
DOIs	https://doi.org/10.1080/0284186X.2021.1889659
Publication status	Published - Jul 2021

Keywords

COVID-19
SARS-CoV-2
cancer
comorbidity
prognosis
survival

Documents & Links

10.1080/0284186X.2021.1889659

Open Access VersionFinal published version, 383 KBLicence: CC BY-NC

Cite this

Ehmsen, S., Jakobsen, L. H., Lendorf, M. E., Eefsen, R. L., Bentsen, L., Knoop, A. S., Aggerholm-Pedersen, N., Skuladottir, H., Herrstedt, J., Jensen, L. H., Rotbøl, C., Damm, M. B., Wedervang, K., Glenthøj, A., Ryg, J., Frederiksen, H., & Kodahl, A. R. (2021). Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study. Acta Oncologica, 60(7), 859-865. https://doi.org/10.1080/0284186X.2021.1889659

@article{a5a946ac40ef47a1b7db6a4da7ce1fa5,

title = "Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study",

abstract = "BACKGROUND: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis.METHODS: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study's primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen.RESULTS: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39).CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.",

keywords = "COVID-19, SARS-CoV-2, cancer, comorbidity, prognosis, survival",

author = "S Ehmsen and Jakobsen, {L H} and Lendorf, {M E} and Eefsen, {R L} and L Bentsen and Knoop, {A S} and N Aggerholm-Pedersen and H Skuladottir and J Herrstedt and Jensen, {L H} and C Rotb{\o}l and Damm, {M B} and K Wedervang and A Glenth{\o}j and J Ryg and H Frederiksen and Kodahl, {A R}",

year = "2021",

month = jul,

doi = "10.1080/0284186X.2021.1889659",

language = "English",

volume = "60",

pages = "859--865",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden",

number = "7",

}

Ehmsen, S, Jakobsen, LH, Lendorf, ME, Eefsen, RL, Bentsen, L, Knoop, AS, Aggerholm-Pedersen, N, Skuladottir, H, Herrstedt, J, Jensen, LH, Rotbøl, C, Damm, MB, Wedervang, K, Glenthøj, A, Ryg, J , Frederiksen, H & Kodahl, AR 2021, 'Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study', Acta Oncologica, vol. 60, no. 7, pp. 859-865. https://doi.org/10.1080/0284186X.2021.1889659

TY - JOUR

T1 - Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers

T2 - a Danish nationwide cohort study

AU - Ehmsen, S

AU - Jakobsen, L H

AU - Lendorf, M E

AU - Eefsen, R L

AU - Bentsen, L

AU - Knoop, A S

AU - Aggerholm-Pedersen, N

AU - Skuladottir, H

AU - Herrstedt, J

AU - Jensen, L H

AU - Rotbøl, C

AU - Damm, M B

AU - Wedervang, K

AU - Glenthøj, A

AU - Ryg, J

AU - Frederiksen, H

AU - Kodahl, A R

PY - 2021/7

Y1 - 2021/7

N2 - BACKGROUND: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis.METHODS: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study's primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen.RESULTS: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39).CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.

AB - BACKGROUND: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis.METHODS: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study's primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen.RESULTS: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39).CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.

KW - COVID-19

KW - SARS-CoV-2

KW - cancer

KW - comorbidity

KW - prognosis

KW - survival

U2 - 10.1080/0284186X.2021.1889659

DO - 10.1080/0284186X.2021.1889659

M3 - Journal article

C2 - 33646071

SN - 0284-186X

VL - 60

SP - 859

EP - 865

JO - Acta Oncologica

JF - Acta Oncologica

IS - 7

ER -

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

Abstract

Keywords

Documents & Links

Fingerprint

Cite this